rheumatology
Medicines

RA drug fails in inflammation in CVD

Methotrexate has no role in the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction or coronary artery disease. Results from the Cardiovascular Inflammation Reduction Trial (CIRT) of low-dose methotrexate versus placebo in almost 5,000 patients found no impact on laboratory measures of inflammation or clinical end points. Patients also had ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic